BRCA2 and medulloblastoma: There is a possibility to expand HRD targeted therapy using LP-184 in other cancers such as NSCLC and AML (5) as well as subgroups of the rare cancer medulloblastoma carrying germline mutations in PALB2 and BRCA2 (39).